Sanofi

ChapsVision acquires Sinequa; Answer ALS and Cedars-Sinai release largest ALS iPSC and bio data repository; Healx to use Sanofi compound with AI platform Healnet; Scale Biosciences and BioLegend launch TotalSeq Phenocyte single-cell protein profiling solution; GeneDx introduces GeneDx Discover data visualization tool; Model N integrates generative AI and data capabilities; NCSA launches DeltaAI; Sapio Sciences and Waters Corporation enhance lab productivity; CapeStart debuts MadeAi platform; Trogenix unveils cancer treatment platform; Exagen submits new SLE and RA biomarkers for approval; C-Path launches GEM-PD initiative; BioNTech acquires Biotheus; Stand Up To Cancer collaborates with Johnson & Johnson on AL amyloidosis treatment; Nxera and Antiverse partner for GPCR antibody design; CCRM Nordic, Sahlgrenska Academy, and Sahlgrenska University Hospital form ATMP partnership; BC Platforms, Modirum Platforms, and VEIL.AI deploy software for EHDS2 framework; Evogene collaborates with Google Cloud on generative AI for small molecule design; Parse Biosciences launches GigaLab for single cell sequencing; Gingko Bioworks introduces Antibody Developability product.

The article discusses the importance of enabling JavaScript for optimal app performance.

Sanofi plans to change its policy on discounts for U.S. hospitals serving low-income and uninsured patients, requiring pharmacy and medical claims info before providing federally mandated discounts under the 340B program. This move aims to eliminate prohibited duplicated discounts and diversion of 340B drugs.

Bloomberg connects decision makers to a dynamic network for global business and financial information, news, and insights.

The Antihistamine Drugs Market is projected to grow from USD 279.74 million in 2024 to USD 381.39 million by 2030, driven by rising allergies, a growing geriatric population, and innovations in drug formulation. Key players include Johnson & Johnson, Sanofi, Pfizer, and Bayer. Challenges include market saturation, side effects, and stringent regulations.

PMEA 2024, held on 21 November at the Sheraton Grand in London, recognized excellence in pharmaceutical marketing with 17 categories, including a new category for low- and middle-income countries. Sanofi and Regeneron won Excellence in Engaging and Educating Patients, Roche won Excellence in Low- and Middle-Income Countries, and Amgen was named PMEA Company of the Year.

Conference on global health and clinical trials addresses bioethics, regulations, patient recruitment, site selection, real-world data, data integration, outsourcing, vendor management, quality in trial conduct, risk-based monitoring, clinical auditing, financial planning, and innovative technologies. Focuses on networking, case studies, presentations, and round tables.

The Global Clinical Trials Connect 2025 conference will discuss futuristic advancements in clinical trials, focusing on innovative strategies, new technologies, and quality collaborations to address increased complexity. Topics include patient recruitment, site selection, real-world data, and risk-based monitoring, among others. The event targets senior-level professionals from pharmaceutical, bio-tech, and CRO companies, offering networking and case study opportunities.

The Global Clinical Trials Connect 2025 conference will discuss futuristic advancements in clinical trials, focusing on innovative strategies, new technologies, and quality collaborations to address increased complexity. Topics include patient recruitment, site selection, data integration, outsourcing, and risk-based monitoring. The event targets senior-level professionals from pharmaceutical, bio-tech, and CRO companies, offering networking and case study presentations.